BPMC241220P165000
- 0.00
- 0.000.00%
Blueprint Medicines Newsroom
JMP Securities Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $125
TD Cowen Maintains Blueprint Medicines(BPMC.US) With Buy Rating
H.C. Wainwright Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $135
Needham Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $135
Morgan Stanley Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Maintains Target Price $120
Needham Reiterates Buy on Blueprint Medicines, Maintains $135 Price Target
Blueprint Medicines Analyst Ratings
J.P. Morgan Initiates Blueprint Medicines(BPMC.US) With Buy Rating, Announces Target Price $126
Barclays Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Maintains Target Price $105
Mixed Efficacy and Safety Profiles Lead to Hold Rating for Blueprint Medicines and Cogent Biosciences
A Quick Look at Today's Ratings for Blueprint Medicines(BPMC.US), With a Forecast Between $105 to $135
Wells Fargo Maintains Overweight on Blueprint Medicines, Lowers Price Target to $151
A Quick Look at Today's Ratings for Blueprint Medicines(BPMC.US), With a Forecast Between $105 to $155
Blueprint Medicines Analyst Ratings
Needham Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $133
Needham Reiterates Buy on Blueprint Medicines, Maintains $133 Price Target
Barclays Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Maintains Target Price $105
Blueprint Medicines Analyst Ratings
Piper Sandler Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Raises Target Price to $109
Morgan Stanley Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Maintains Target Price $120